BIOCRYST PHARMACEUTICALS INC 8-K

What Happened

• BioCryst Pharmaceuticals, Inc. (BCRX) filed an 8-K on June 12, 2026 reporting results of its June 11, 2026 Annual Meeting. Stockholders approved an amended and restated Stock Incentive Plan that increases the number of shares available for issuance under the plan by 7,000,000 shares. The amended plan document is filed as Exhibit 10.1 to the 8-K.

Key Details

• Annual Meeting date: June 11, 2026; 8-K filed June 12, 2026.
• Approved increase of 7,000,000 shares under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (amended and restated plan filed as Exhibit 10.1).
• Elected three directors to terms ending at the 2029 annual meeting.
• Ratified Ernst & Young LLP as independent registered public accountants for 2026 and held a non‑binding advisory (say-on-pay) vote on executive compensation.

Why It Matters

• The 7 million‑share increase expands the pool available for equity awards (stock options, restricted stock, etc.), which management can use for hiring, retention and incentives; that can lead to future dilution for existing shareholders depending on grants made.
• Director elections and auditor ratification are governance items investors watch for board continuity and financial oversight.
• The advisory vote on executive compensation provides investor feedback on pay practices, though it is non‑binding.

Keywords: stock incentive plan, equity compensation, shares, dilution, director election, auditor ratification, annual meeting.